» Articles » PMID: 35360076

Associations Between Abdominal Obesity Indices and Nonalcoholic Fatty Liver Disease: Chinese Visceral Adiposity Index

Overview
Specialty Endocrinology
Date 2022 Apr 1
PMID 35360076
Authors
Affiliations
Soon will be listed here.
Abstract

Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver metabolic disease worldwide. Up to 70%-80% of patients with NAFLD were obese, especially abdominal obesity. Many indicators of abdominal obesity have been reported, including waist circumference (WC), visceral obesity index (VAI), lipid accumulation (LAP), and Chinese VAI (CVAI). However, few studies investigated the associations between these indices with NAFLD. This present study aims to explore the associations between abdominal obesity indices with NAFLD. A total of 7,238 participants were involved in the cross-sectional study, and 1,584 participants were included in the longitudinal study from Jidong communities. NAFLD was assessed by abdominal ultrasonography. The trajectory of WC, VAI, LAP, and CVAI during 2013-2016 was identified by a group-based trajectory model. The logistic regression and Cox proportional hazards models analyzed the correlations and causality between abdominal obesity indices with NAFLD. In this study, the prevalence and incidence of NAFLD are approximately 44% and 26%, respectively. In the cross-sectional study, WC, VAI, LAP, and CVAI are associated with NAFLD. After adjustment for potential confounders, the moderate-rising and high-rising groups of CVAI had the highest risk of NAFLD in longitudinal analysis (hazard ratio (HR): 3.903, 95%CI: 2.434-6.259; HR: 5.694 95%CI: 3.098-10.464, respectively). Receiving operating characteristic curves show that CVAI has the best diagnostic value for NAFLD (area under the curve (AUC) = 0.868). CVAI is independently associated with the risk of NAFLD and may also have an important value to the diagnosis of NAFLD.

Citing Articles

Obesity Among Healthcare Workers in Al Ahsa, Saudi Arabia: Prevalence, Predictors, and Workplace Health Implications.

Hassanein S, Al Khatib A, AlMoosa O, Abdrbo A Healthcare (Basel). 2025; 13(5).

PMID: 40077090 PMC: 11899652. DOI: 10.3390/healthcare13050528.


Serum uric acid trajectories and risk of metabolic dysfunction-associated steatotic liver disease in China: a 2019-2021 cohort health survey.

Shi D, Tan Q, Zhang Y, Qi X, Xu X, Xu G BMC Public Health. 2025; 25(1):653.

PMID: 39962427 PMC: 11834244. DOI: 10.1186/s12889-024-21214-0.


Non-alcoholic fatty liver disease: Dietary and nutraceutical approaches.

Cogorno L, Formisano E, Vignati A, Prigione A, Tramacere A, Borgarelli C Liver Res. 2025; 7(3):216-227.

PMID: 39958388 PMC: 11791914. DOI: 10.1016/j.livres.2023.08.005.


Associations between Chinese Visceral Adiposity Index and the Risk of Metabolic Dysfunction-associated Steatotic Liver Disease and Liver Fibrosis: A Large Cross-sectional Study.

Liu H, Deng M, Luo G, Chen J Iran J Med Sci. 2025; 50(1):11-21.

PMID: 39957808 PMC: 11829064. DOI: 10.30476/ijms.2024.100818.3335.


Metabolic and Hepatic Profiles of Non-Obese and Obese Metabolic Dysfunction-Associated Steatotic Liver Disease in Adolescents: The Role of FibroScan Parameters,Fibroblast Growth Factor-21, and Cytokeratin-18.

Keskin M, Arsoy H, Kara O, Sarandol E, Beyaz A, Koca N Turk J Gastroenterol. 2025; .

PMID: 39910885 PMC: 11900013. DOI: 10.5152/tjg.2025.24760.


References
1.
Vassilatou E, Lafoyianni S, Vassiliadi D, Ioannidis D, Paschou S, Mizamtsidi M . Visceral adiposity index for the diagnosis of nonalcoholic fatty liver disease in premenopausal women with and without polycystic ovary syndrome. Maturitas. 2018; 116:1-7. DOI: 10.1016/j.maturitas.2018.06.013. View

2.
Xia M, Lin H, Chen L, Wu L, Ma H, Li Q . Association of visceral adiposity and its longitudinal increase with the risk of diabetes in Chinese adults: A prospective cohort study. Diabetes Metab Res Rev. 2018; 34(7):e3048. DOI: 10.1002/dmrr.3048. View

3.
Zhao L, Huang G, Xia F, Li Q, Han B, Chen Y . Neck circumference as an independent indicator of visceral obesity in a Chinese population. Lipids Health Dis. 2018; 17(1):85. PMC: 5902833. DOI: 10.1186/s12944-018-0739-z. View

4.
Sung K, Jeong W, Wild S, Byrne C . Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care. 2012; 35(4):717-22. PMC: 3308286. DOI: 10.2337/dc11-1853. View

5.
Musso G, Cassader M, Gambino R . Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat Rev Drug Discov. 2016; 15(4):249-74. DOI: 10.1038/nrd.2015.3. View